BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1199 related articles for article (PubMed ID: 34521385)

  • 1. Development and validation of a risk prediction nomogram for in-stent restenosis in patients undergoing percutaneous coronary intervention.
    He W; Xu C; Wang X; Lei J; Qiu Q; Hu Y; Luo D
    BMC Cardiovasc Disord; 2021 Sep; 21(1):435. PubMed ID: 34521385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment and validation of a risk model for prediction of in-hospital mortality in patients with acute ST-elevation myocardial infarction after primary PCI.
    Gao N; Qi X; Dang Y; Li Y; Wang G; Liu X; Zhu N; Fu J
    BMC Cardiovasc Disord; 2020 Dec; 20(1):513. PubMed ID: 33297955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for revascularization and in-stent restenosis in patients with triple-vessel disease after second-generation drug-eluting stent implantation: a retrospective analysis.
    Zeng M; Yan X; Wu W
    BMC Cardiovasc Disord; 2021 Sep; 21(1):446. PubMed ID: 34535088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronary CT angiography-derived quantitative markers for predicting in-stent restenosis.
    Tesche C; De Cecco CN; Vliegenthart R; Duguay TM; Stubenrauch AC; Rosenberg RD; Varga-Szemes A; Bayer RR; Yang J; Ebersberger U; Baquet M; Jochheim D; Hoffmann E; Steinberg DH; Chiaramida SA; Schoepf UJ
    J Cardiovasc Comput Tomogr; 2016; 10(5):377-83. PubMed ID: 27431607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk investigation of in-stent restenosis after initial implantation of intracoronary drug-eluting stent in patients with coronary heart disease.
    Xi H; Liu J; Xu T; Li Z; Mou X; Jin Y; Xia S
    Front Cardiovasc Med; 2023; 10():1117915. PubMed ID: 36970340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining clinical and angiographic variables for estimating risk of target lesion revascularization after drug eluting stent placement.
    Stolker JM; Cohen DJ; Kennedy KF; Pencina MJ; Arnold SV; Kleiman NS; Spertus JA;
    Cardiovasc Revasc Med; 2017; 18(3):169-176. PubMed ID: 28041858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prediction model based on platelet parameters, lipid levels, and angiographic characteristics to predict in-stent restenosis in coronary artery disease patients implanted with drug-eluting stents.
    Gai MT; Zhu B; Chen XC; Liu F; Xie X; Gao XM; Ma X; Fu ZY; Ma YT; Chen BD
    Lipids Health Dis; 2021 Sep; 20(1):118. PubMed ID: 34587955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
    Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of insulin resistance on in-stent restenosis in patients undergoing coronary drug-eluting stent implantation after long-term angiographic follow-up.
    Zhao LP; Xu WT; Wang L; Li H; Shao CL; Gu HB; Chan SP; Xu HF; Yang XJ
    Coron Artery Dis; 2015 Jan; 26(1):5-10. PubMed ID: 25211654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI.
    Song T; Fu Y; Wang Y; Li W; Zhao J; Wang X; Wang H; Zhao Y; Fu X
    BMC Cardiovasc Disord; 2021 Jan; 21(1):24. PubMed ID: 33413149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors of in-stent restenosis among coronary artery disease patients with syphilis undergoing percutaneous coronary intervention: a retrospective study.
    Zhang L; Wang Y; Zhang Z; Liang H; Wu L; Ni L; Gao G; Yang D; Zhao H; Xiao J
    BMC Cardiovasc Disord; 2021 Sep; 21(1):438. PubMed ID: 34525967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The characteristics and risk factors of in-stent restenosis in patients with percutaneous coronary intervention: what can we do.
    Wang P; Qiao H; Wang R; Hou R; Guo J
    BMC Cardiovasc Disord; 2020 Dec; 20(1):510. PubMed ID: 33276720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of stent diameter and length on in-stent restenosis after DES vs BMS implantation in patients needing large coronary stents-A clinical and health-economic evaluation.
    Zbinden R; von Felten S; Wein B; Tueller D; Kurz DJ; Reho I; Galatius S; Alber H; Conen D; Pfisterer M; Kaiser C; Eberli FR
    Cardiovasc Ther; 2017 Feb; 35(1):19-25. PubMed ID: 27662632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Nomogram for Predicting In-Stent Restenosis Risk in Patients Undergoing Percutaneous Coronary Intervention: A Population-Based Analysis.
    Luo Y; Tan N; Zhao J; Li Y
    Int J Gen Med; 2022; 15():2451-2461. PubMed ID: 35264881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between uric acid to albumin ratio and in-stent restenosis in patients with coronary artery disease undergoing drug-eluting stenting.
    Liu W; Ding K; Bao J; Hu Y; Gui Y; Ye L; Wang L
    Coron Artery Dis; 2023 Dec; 34(8):589-594. PubMed ID: 37855441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiographic Scoring System for Predicting Successful Percutaneous Coronary Intervention of In-Stent Chronic Total Occlusion.
    Gong M; Peng H; Wu Z; Li W; Lv Y; Lv Y; Zheng Z; An T; Zhang J; Lv M; Li X; Gong H; Mao Y; Liu J
    J Cardiovasc Transl Res; 2021 Aug; 14(4):598-609. PubMed ID: 33409961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravascular ultrasound assessment of optimal stent area to prevent in-stent restenosis after zotarolimus-, everolimus-, and sirolimus-eluting stent implantation.
    Song HG; Kang SJ; Ahn JM; Kim WJ; Lee JY; Park DW; Lee SW; Kim YH; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2014 May; 83(6):873-8. PubMed ID: 22815193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiography and Optical Coherence Tomography Assessment of the Drug-Coated Balloon ESSENTIAL for the Treatment of In-Stent Restenosis.
    de la Torre Hernández JM; Garcia Camarero T; Lozano Ruiz-Poveda F; Urbano-Carrillo CA; Sánchez Pérez I; Cano-García M; Saez R; Andrés Morist A; Molina E; Pinar E; Torres A; Lezcano EJ; Gutierrez H; Arnold RJ; Zueco J
    Cardiovasc Revasc Med; 2020 Apr; 21(4):508-513. PubMed ID: 31401071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood Pressure Levels at the Time of Percutaneous Coronary Revascularization and Risk of Coronary In-Stent Restenosis.
    Tocci G; Barbato E; Coluccia R; Modestino A; Pagliaro B; Mastromarino V; Giovannelli F; Berni A; Volpe M
    Am J Hypertens; 2016 Apr; 29(4):509-18. PubMed ID: 26271109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.